Astilbin inhibits proliferation of rat aortic smooth muscle cells induced by angiotensin II and down-regulates expression of protooncogene

Abstract

This study examined the effect of astilbin on the proliferation of rat aortic smooth muscle cells (RASMCs) induced by angiotensin II (AngII) and explored the possible mechanisms. Cell proliferation model of RASMCs was induced by treatmente with AngII. Cells were randomly divided to 8 groups. Normally cultured VSMCs serves as blank control group; in AngII model group, cells were treated with AngII at 10⁻⁷ mol/L; in three astilbin groups, cells were treated with 10, 15, 30 mg/L of astilbin; in three AngII+astilbin groups, cells were treated with AngII (at 10⁻⁷ mol/L) and astilbin at 10, 15, 30 mg/L. Cell proliferation ability was detected by MTT method and the cell cycles and proliferation index were flow cytometrically determined. The expression of c-myc mRNA was assessed by using reverse transcription polymerase chain reaction (RT-PCR), and the expression of NF-κB in RASMCs was immunocytochemically observed. Our results showed that MTT metabolism in RASMCs in the basic and AngII stimulated situation was inhibited by astilbin, and the cells numbers of G₀/G₁ phase were increased and that of G₂/S phase were decreased markedly. Not only highly expression of c-myc gene stimulated by AngII could be inhibited by Astilbin significantly, but also the expression of NF-κB protein can be down regulated by Astilbin. We are led to conclude that astilbin astilbin can inhibit the AngII-mediated proliferation of RASMCs by blocking the transition of RASMCs from G₀/G₁ phase to S phase and by down-regulating the expression of NF-κB, c-myc gene.

Keywords

astilbin / vascular smooth muscle cells / proliferation / angiotensin II / protooncogene / NF-κB

References

[1] SchmaussD., WeisM.. Cardiac allograft vasculopathy: recent developments. Circulation, 2008, 117(16): 2131-2141

[2] Martínez-DolzL., AlmenarL., ReganonE., et al.. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant, 2008, 27(7): 760-766

[3] YanR., XuQ.. Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin-activated jurkat cells. Pharmacol Res, 2001, 44(2): 135-139

[4] GaoS.H., LiP., PanT.C., et al.. Astilbin induces apoptosis of activated T cells of mouse heart transplantation model with acute rejection in vitro. Chin J Exp Surg (Chinese), 2004, 21(4): 502

[5] HanL.K., NinomiyaH., TangiguchiM., et al.. Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes. J Nat Prod, 1998, 61(8): 1006-1011

[6] GaoS.H., PanT.C.. Protective effects of Astilbin on rat isolated heart reperfusion injury. Chin J Pract Chin Mod Med (Chinese), 2003, 3(16): 1693-1694

[7] ZhaoJ., LiP., ZhangY., et al.. The inhibitory effect of Astilbin on the arteriosclerosis of murine thoracic aorta transplantat. J Huazhong Univ Sci Technolog [Med Sci], 2009, 29(2): 212-214

[8] Moien-AfshariF., McManusB.M., LaherI.. Immunosuppression and transplant vascular disease: benefits and adverse effects. Pharmacol Ther, 2003, 100(2): 141-156

[9] GaoS.H., ChenT., PanT.C.. Effect of Astilbin on expression of Bax,Bcl-2 and caspase-3 in allograft reactive T cells. Chin J Pract Chin Mod Med (Chinese), 2003, 3(16): 2110-2111

[10] GaoS.H., LiP., PanT.C.. Effect of astilbin on expression of Fas, FasL, TNF-R1 and TNF-R2 in allograft reactive T cells. Chin J Pract Chin Mod Med (Chinese), 2004, 4(17): 217-218

[11] CaiY., ChenT., XuQ., et al.. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm Res, 2003, 52(8): 334-340

[12] CaiY., ChenT., XuQ., et al.. Astilbin suppresses delayed-type hypersensitivity by inhibiting lymphocyte migration. J Pharm Pharmacol, 2003, 55(5): 691-696

[13] RobbianiD.F., BothmerA., CallenE., et al.. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell, 2008, 135(6): 1028-1038

[14] KumarN., PatowaryA., SivasubbuS., et al.. Silencing c-MYC expression by targeting quadruplex in P1 promoter using locked nucleic acid trap. Biochemistry, 2008, 47(50): 13179-88

[15] NahmiasC., StrosbergD.. The angiotensin AT recep tor: searching for signal transduction pathways and physiological function. Trends Pharmacol Sci, 1995, 16: 223-225

[16] CottermanR., JinV.X., KrigS.R., et al.. SN-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res, 2008, 68(23): 9654-9662

[17] KangO.H., JangH.J., ChaeH.S., et al.. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol Res, 2009, 59(5): 330-337